Results 21 to 30 of about 22,035 (254)

Pooled resistance analyses of darunavir once-daily regimens and formulations across 10 clinical studies of treatment-naïve and treatment-experienced patients with human immunodeficiency virus-1 infection

HIV Research & Clinical Practice, 2020
Background The efficacy and high barrier to resistance of darunavir have been demonstrated across diverse populations with HIV-1 infection. Objective To evaluate post-baseline resistance among patients in studies of once-daily (QD) darunavir-based ...
Erkki Lathouwers, Sareh Seyedkazemi, Donghan Luo, Kimberley Brown, Sandra De Meyer, Eric Y. Wong   +5 more
doaj   +1 more source

Once-daily dolutegravir versus darunavir plus cobicistat in adults at the time of primary HIV-1 infection: the OPTIPRIM2-ANRS 169 randomized, open-label, Phase 3 trial.

Journal of Antimicrobial Chemotherapy, 2022
BACKGROUND Whether integrase strand transfer inhibitors (INSTIs) can decrease HIV-1 DNA levels more rapidly than boosted PIs during primary HIV-1 infection (PHI) is unknown.
A. Chéret, Rebecca Bauer, V. Meiffrédy, Pauline Lopez, F. Ajana, K. Lacombe, P. Morlat, C. Lascoux, J. Reynes, R. Calin, S. Abel, C. Goujard, C. Rouzioux, V. Avettand-Fenoel, L. Meyer   +14 more
semanticscholar   +1 more source

Rapid initiation of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in acute and early HIV-1 infection: a DIAMOND subgroup analysis

HIV Research & Clinical Practice, 2021
Background: Treatment during acute or early human immunodeficiency virus (HIV)-1 infection is associated with immunologic and virologic benefits. Objective: To evaluate darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) efficacy/safety ...
Keith Dunn, Rachel Rogers, Richard Bruce Simonson, Donghan Luo, Shubin Sheng, Purnima T. Kassam, Sareh Seyedkazemi, Hélène Hardy   +7 more
doaj   +1 more source

Third‐line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource‐limited settings: ACTG A5288 strategy trial

Journal of the International AIDS Society, 2022
ACTG A5288 was a strategy trial conducted in diverse populations from multiple continents of people living with HIV (PLWH) failing second‐line protease inhibitor (PI)‐based antiretroviral therapy (ART) from 10 low‐ and middle‐income countries (LMICs ...
A. Avihingsanon, M. Hughes, R. Salata, C. Godfrey, Caitlyn McCarthy, P. Mugyenyi, E. Hogg, R. Gross, S. W. Cardoso, Aggrey Bukuru, Mumbi Makanga, Sharlaa Badal‐aesen, V. Mave, Beatrice Wangari Ndege, S. N. Fontain, W. Samaneka, R. Secours, M. van Schalkwyk, R. Mngqibisa, L. Mohapi, J. Valencia, P. Sugandhavesa, E. Montalbán, Cornelius Munyanga, M. Chagomerana, B. Santos, N. Kumarasamy, C. Kanyama, R. Schooley, J. Mellors, C. Wallis, A. Collier, B. Grinsztejn   +32 more
semanticscholar   +1 more source

Drug-Drug Interactions Among Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Medications [PDF]

, 2015
One-fourth of individuals diagnosed with the human immunodeficiency virus concomitantly have the hepatitis C virus infection. Since the discovery of highly active antiretroviral therapy, liver complications have become the leading cause of morbidity and ...
Gandhi, Mona A., Kaur, Kirpal, Slish, Judianne   +2 more
core   +2 more sources

Antiviral Activity and Safety of Darunavir/Cobicistat for the Treatment of COVID-19

Open Forum Infectious Diseases, 2020
Background We aimed to evaluate the antiviral activity and safety of darunavir/cobicistat (DRV/c) in treating COVID-19 patients. Methods In this single-center, randomized, and open-label trial, mild patients with polymerase chain reaction (PCR)–confirmed
Jun Chen, L. Xia, Li Liu, Qingnian Xu, Y. Ling, Dan Huang, Wei Huang, Shuli Song, Shuibao Xu, Yi Shen, Hongzhou Lu   +10 more
semanticscholar   +1 more source

Changes in Quality of Sleep, Mood, and Other Neuropsychiatric Symptoms After Switching Dolutegravir/Lamivudine/Abacavir to Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in a Randomized Study of People With Human Immunodeficiency Virus With Poor Sleep Quality: GESIDA 10418

Open Forum Infectious Diseases, 2022
Background Although switching antiretroviral therapy (ART) in people with human immunodeficiency virus experiencing insomnia due to dolutegravir-related neurotoxicity is well founded upon evidence, there is a lack of proof in regard to the outcome of ...
Alfonso Cabello-Úbeda, A. Baeza, Jesús Troya García, S. de la Fuente Moral, María Novella Mena, A. P. Martínez, R. Micán, M. Górgolas, Guillermo Cuevas Tascón, A. D. de Santiago, José Sanz Morerno, D. R. Crestelo, C. B. Arenzana, José Ignacio Bernardino Serna, M. Almirón, J. Cano, H. Esteban, I. Pérez-Valero   +17 more
semanticscholar   +1 more source

The Effect of Solvents and Drying Temperature on the Physicochemical Properties of Darunavir and Darunavir Ethanolate Substances

Разработка и регистрация лекарственных средств, 2021
Introduction. Usage of aggressive conditions (solvents, high temperature, etc.) in a dosage form manufacturing can lead to a change in the properties of a pharmaceutical substance.
S. A. Zolotov, I. A. Dain, N. B. Demina, A. S. Zolotova, E. S. Ponomarev   +4 more
doaj   +1 more source

Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1 [PDF]

, 2019
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg was investigated through 96 weeks in EMERALD (NCT02269917). Virologically-suppressed, HIV-1-positive treatment-experienced adults (previous non-darunavir virologic ...
Ajana, F, Arribas, JR, Bailey, J, Benson, P, Berenguer, J, Bhatti, L, Blaxhult, A, Brar, I, Bredeek, UF, Brinson, C, Brown, Kimberley, Brunetta, J, Casado, J, Clarke, A, Conway, B, Cotte, L, Crofoot, G, Cunningham, D, Cunningham, Douglas, de Vente, J, De Wit, S, De Wit, Stéphane, DeJesus, E, Dietz, C, Dretler, R, Eron, J, Eron, Joseph J, Fehr, J, Felizarta, F, Fichtenbaum, C, Flamholc, L, Florence, E, Galindo, MJ, Gallant, J, Gasiorowski, J, Gatell, JM, Gathe, J, Gazzard, BG, Girardy, P-M, Gisslèn, M, Gutierrez, F, Gutierrez, MDM, Hagins, D, Halota, W, Henn, S, Henry, WK, Horban, A, Hufkens, Veerle, Huhn, G, Iribarren, JA, Jain, M, Jezorwski, John, Johnson, MA, Katlama, C, Klein, M, Knobel, H, Lathouwers, Erkki, Lucasti, C, Martorell, C, McDonald, C, Mills, A, Molina, J-M, Morales-Ramirez, J, Mounzer, K, Moutschen, M, Murphy, D, Nahass, R, Negredo, E, Olivet, H, Opsomer, Magda, Orkin, C, Orkin, Chloe, Osiyemi, O, Perez-Valero, I, Petrovic, Romana, Piekarska, A, Pineda, JA, Podzamczer, D, Poizot-Martin, I, Portilla Sogorb, J, Post, F, Post, Frank A, Prelutsky, D, Pulido, F, Pulido, Federico, Rachlis, A, Raffi, F, Ramgopal, M, Rashbaum, B, Rauch, A, Rey, D, Reynes, J, Ricart, C, Richmond, G, Rivero, A, Ruane, P, Santos Gil, I, Scarsella, A, Scribner, A, Shafran, S, Shalit, P, Shamblaw, D, Slim, J, Stoeckle, M, Tashima, K, Teicher, E, Thalme, A, Ustianowski, A, Van Landuyt, Erika, Van Wijngaerden, E, Vandekerckhove, Linos, Vandercam, B, Voskuhl, G, Walmsley, S, Ward, D, Waters, L, Wilkin, A, Witor, A, Yazdanpanah, Y   +118 more
core   +2 more sources

Acute myocardial infarction associated with abacavir and tenofovir based antiretroviral drug combinations in the United States

AIDS Research and Therapy, 2021
Introduction Although individual antiretroviral drugs have been shown to be associated with elevated cardiovascular disease (CVD) risk, data are limited on the role of antiretroviral drug combinations.
Kunchok Dorjee, Manisha Desai, Tsering Choden, Sanjiv M. Baxi, Alan E. Hubbard, Arthur L. Reingold   +5 more
doaj   +1 more source